Aliskiren/hydrochlorothiazide explained

Type:	combo
Component1:	Aliskiren
Class1:	Renin inhibitor
Component2:	Hydrochlorothiazide
Class2:	Diuretic
Tradename:	Tekturna HCT, Rasilez HCT, others
Dailymedid:	Aliskiren_hemifumarate_and_hydrochlorothiazide
Routes Of Administration:	By mouth
Atc Prefix:	C09
Atc Suffix:	XA52
Legal Us:	Rx-only
Legal Eu:	Rx-only
Kegg:	D10289

Aliskiren/hydrochlorothiazide, sold under the brand name Tekturna HCT among others, is a fixed-dose combination medication for the treatment of hypertension (high blood pressure).^[1] ^[2] ^[3] ^[4] It contains aliskiren, a renin inhibitor, and hydrochlorothiazide, a diuretic. It is taken by mouth.

The most common side effect is diarrhea.

Aliskiren/hydrochlorothiazide was approved for medical use in the United States in January 2008,^[5] and for use in the European Union in January 2009.

Medical uses

Aliskiren/hydrochlorothiazide is indicated for the treatment of essential hypertension in adults.

External links

Web site: Aliskiren hemifumarate mixture with hydrochlorothiazide . U.S. National Library of Medicine. Drug Information Portal.

Notes and References

Web site: Tekturna HCT- aliskiren hemifumarate and hydrochlorothiazide tablet, film coated . DailyMed . 7 January 2020 . 26 August 2020.
Web site: Rasilez HCT EPAR . European Medicines Agency . 17 September 2018 . 27 August 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Chrysant SG . Aliskiren-hydrochlorothiazide combination for the treatment of hypertension . Expert Review of Cardiovascular Therapy . 6 . 3 . 305–14 . March 2008 . 18327992 . 10.1586/14779072.6.3.305 . 44410886 .
Sureshkumar KK . Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy . Vascular Health and Risk Management . 4 . 6 . 1205–20 . 2008 . 19337534 . 2663460 . 10.2147/vhrm.s3364 . free .
Web site: Drug Approval Package: Tekturna HCT (aliskiren/hydrochlorothiazide) NDA #022107 . U.S. Food and Drug Administration (FDA) . 24 December 1999 . 27 August 2020.